Gilead touts 'astounding' Yescarta survival results at 3 years by Carly Helfand Sunday, December 8, 2019 How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.
